nodes	percent_of_prediction	percent_of_DWPC	metapath
Clavulanate—Anaphylactic shock—Degarelix—prostate cancer	0.00538	0.00538	CcSEcCtD
Clavulanate—Haemoglobin—Ethinyl Estradiol—prostate cancer	0.0052	0.0052	CcSEcCtD
Clavulanate—Haemorrhage—Ethinyl Estradiol—prostate cancer	0.00518	0.00518	CcSEcCtD
Clavulanate—Swelling—Mitoxantrone—prostate cancer	0.00516	0.00516	CcSEcCtD
Clavulanate—Urticaria—Estrone—prostate cancer	0.00515	0.00515	CcSEcCtD
Clavulanate—Pain—Nilutamide—prostate cancer	0.00515	0.00515	CcSEcCtD
Clavulanate—Thrombocytopenia—Cabazitaxel—prostate cancer	0.00496	0.00496	CcSEcCtD
Clavulanate—Erythema multiforme—Ethinyl Estradiol—prostate cancer	0.00489	0.00489	CcSEcCtD
Clavulanate—Pain—Estradiol valerate/Dienogest—prostate cancer	0.00484	0.00484	CcSEcCtD
Clavulanate—Pruritus—Estramustine—prostate cancer	0.0048	0.0048	CcSEcCtD
Clavulanate—Diarrhoea—Estramustine—prostate cancer	0.00465	0.00465	CcSEcCtD
Clavulanate—Pain—Degarelix—prostate cancer	0.0046	0.0046	CcSEcCtD
Clavulanate—Pruritus—Estrone—prostate cancer	0.00459	0.00459	CcSEcCtD
Clavulanate—Diarrhoea—Abiraterone—prostate cancer	0.00451	0.00451	CcSEcCtD
Clavulanate—Urticaria—Estradiol valerate/Dienogest—prostate cancer	0.0045	0.0045	CcSEcCtD
Clavulanate—Pain—Cabazitaxel—prostate cancer	0.00434	0.00434	CcSEcCtD
Clavulanate—Vomiting—Estramustine—prostate cancer	0.00432	0.00432	CcSEcCtD
Clavulanate—Swelling—Etoposide—prostate cancer	0.00429	0.00429	CcSEcCtD
Clavulanate—Rash—Estramustine—prostate cancer	0.00428	0.00428	CcSEcCtD
Clavulanate—Haemoglobin—Goserelin—prostate cancer	0.00428	0.00428	CcSEcCtD
Clavulanate—Dermatitis—Estramustine—prostate cancer	0.00428	0.00428	CcSEcCtD
Clavulanate—Urticaria—Degarelix—prostate cancer	0.00428	0.00428	CcSEcCtD
Clavulanate—Pruritus—Nilutamide—prostate cancer	0.00426	0.00426	CcSEcCtD
Clavulanate—Haemorrhage—Goserelin—prostate cancer	0.00426	0.00426	CcSEcCtD
Clavulanate—Hepatitis—Goserelin—prostate cancer	0.00426	0.00426	CcSEcCtD
Clavulanate—Thrombocytopenia—Bicalutamide—prostate cancer	0.00426	0.00426	CcSEcCtD
Clavulanate—Pruritus—Flutamide—prostate cancer	0.00424	0.00424	CcSEcCtD
Clavulanate—Vomiting—Abiraterone—prostate cancer	0.00419	0.00419	CcSEcCtD
Clavulanate—Hypersensitivity—Estradiol valerate/Dienogest—prostate cancer	0.00417	0.00417	CcSEcCtD
Clavulanate—Rash—Abiraterone—prostate cancer	0.00416	0.00416	CcSEcCtD
Clavulanate—Dermatitis—Abiraterone—prostate cancer	0.00415	0.00415	CcSEcCtD
Clavulanate—Hypokalaemia—Mitoxantrone—prostate cancer	0.00414	0.00414	CcSEcCtD
Clavulanate—Vomiting—Estrone—prostate cancer	0.00412	0.00412	CcSEcCtD
Clavulanate—Diarrhoea—Nilutamide—prostate cancer	0.00412	0.00412	CcSEcCtD
Clavulanate—Diarrhoea—Flutamide—prostate cancer	0.0041	0.0041	CcSEcCtD
Clavulanate—Rash—Estrone—prostate cancer	0.00409	0.00409	CcSEcCtD
Clavulanate—Dermatitis—Estrone—prostate cancer	0.00409	0.00409	CcSEcCtD
Clavulanate—Nausea—Estramustine—prostate cancer	0.00403	0.00403	CcSEcCtD
Clavulanate—Pruritus—Estradiol valerate/Dienogest—prostate cancer	0.00401	0.00401	CcSEcCtD
Clavulanate—Erythema multiforme—Conjugated Estrogens—prostate cancer	0.00399	0.00399	CcSEcCtD
Clavulanate—Hypersensitivity—Degarelix—prostate cancer	0.00397	0.00397	CcSEcCtD
Clavulanate—Nausea—Estrone—prostate cancer	0.00385	0.00385	CcSEcCtD
Clavulanate—Vomiting—Nilutamide—prostate cancer	0.00383	0.00383	CcSEcCtD
Clavulanate—Vomiting—Flutamide—prostate cancer	0.00381	0.00381	CcSEcCtD
Clavulanate—Pruritus—Degarelix—prostate cancer	0.00381	0.00381	CcSEcCtD
Clavulanate—Rash—Nilutamide—prostate cancer	0.0038	0.0038	CcSEcCtD
Clavulanate—Dermatitis—Nilutamide—prostate cancer	0.0038	0.0038	CcSEcCtD
Clavulanate—Rash—Flutamide—prostate cancer	0.00378	0.00378	CcSEcCtD
Clavulanate—Dermatitis—Flutamide—prostate cancer	0.00378	0.00378	CcSEcCtD
Clavulanate—Hypersensitivity—Cabazitaxel—prostate cancer	0.00374	0.00374	CcSEcCtD
Clavulanate—Pain—Bicalutamide—prostate cancer	0.00372	0.00372	CcSEcCtD
Clavulanate—Diarrhoea—Degarelix—prostate cancer	0.00368	0.00368	CcSEcCtD
Clavulanate—Thrombophlebitis—Docetaxel—prostate cancer	0.00363	0.00363	CcSEcCtD
Clavulanate—Vomiting—Estradiol valerate/Dienogest—prostate cancer	0.0036	0.0036	CcSEcCtD
Clavulanate—Nausea—Nilutamide—prostate cancer	0.00358	0.00358	CcSEcCtD
Clavulanate—Rash—Estradiol valerate/Dienogest—prostate cancer	0.00357	0.00357	CcSEcCtD
Clavulanate—Dermatitis—Estradiol valerate/Dienogest—prostate cancer	0.00357	0.00357	CcSEcCtD
Clavulanate—Swelling—Docetaxel—prostate cancer	0.00356	0.00356	CcSEcCtD
Clavulanate—Nausea—Flutamide—prostate cancer	0.00356	0.00356	CcSEcCtD
Clavulanate—Thrombophlebitis—Capecitabine—prostate cancer	0.00352	0.00352	CcSEcCtD
Clavulanate—Diarrhoea—Cabazitaxel—prostate cancer	0.00347	0.00347	CcSEcCtD
Clavulanate—Urticaria—Bicalutamide—prostate cancer	0.00346	0.00346	CcSEcCtD
Clavulanate—Swelling—Capecitabine—prostate cancer	0.00345	0.00345	CcSEcCtD
Clavulanate—Vomiting—Degarelix—prostate cancer	0.00342	0.00342	CcSEcCtD
Clavulanate—Toxic epidermal necrolysis—Etoposide—prostate cancer	0.00341	0.00341	CcSEcCtD
Clavulanate—Rash—Degarelix—prostate cancer	0.00339	0.00339	CcSEcCtD
Clavulanate—Haemoglobin—Estradiol—prostate cancer	0.00339	0.00339	CcSEcCtD
Clavulanate—Dermatitis—Degarelix—prostate cancer	0.00339	0.00339	CcSEcCtD
Clavulanate—Haemorrhage—Estradiol—prostate cancer	0.00338	0.00338	CcSEcCtD
Clavulanate—Hepatitis—Estradiol—prostate cancer	0.00338	0.00338	CcSEcCtD
Clavulanate—Nausea—Estradiol valerate/Dienogest—prostate cancer	0.00336	0.00336	CcSEcCtD
Clavulanate—Jaundice cholestatic—Epirubicin—prostate cancer	0.00332	0.00332	CcSEcCtD
Clavulanate—Leukopenia—Goserelin—prostate cancer	0.00332	0.00332	CcSEcCtD
Clavulanate—Vomiting—Cabazitaxel—prostate cancer	0.00322	0.00322	CcSEcCtD
Clavulanate—Convulsion—Goserelin—prostate cancer	0.00321	0.00321	CcSEcCtD
Clavulanate—Hypersensitivity—Bicalutamide—prostate cancer	0.0032	0.0032	CcSEcCtD
Clavulanate—Nausea—Degarelix—prostate cancer	0.0032	0.0032	CcSEcCtD
Clavulanate—Erythema multiforme—Estradiol—prostate cancer	0.00319	0.00319	CcSEcCtD
Clavulanate—Convulsion—Conjugated Estrogens—prostate cancer	0.00318	0.00318	CcSEcCtD
Clavulanate—Haemoglobin—Mitoxantrone—prostate cancer	0.00316	0.00316	CcSEcCtD
Clavulanate—Hepatitis—Mitoxantrone—prostate cancer	0.00315	0.00315	CcSEcCtD
Clavulanate—Haemorrhage—Mitoxantrone—prostate cancer	0.00315	0.00315	CcSEcCtD
Clavulanate—Thrombophlebitis—Prednisone—prostate cancer	0.00313	0.00313	CcSEcCtD
Clavulanate—Pruritus—Bicalutamide—prostate cancer	0.00308	0.00308	CcSEcCtD
Clavulanate—Jaundice cholestatic—Doxorubicin—prostate cancer	0.00308	0.00308	CcSEcCtD
Clavulanate—Anaphylactic shock—Goserelin—prostate cancer	0.00303	0.00303	CcSEcCtD
Clavulanate—Nausea—Cabazitaxel—prostate cancer	0.00301	0.00301	CcSEcCtD
Clavulanate—Anaphylactic shock—Conjugated Estrogens—prostate cancer	0.003	0.003	CcSEcCtD
Clavulanate—Diarrhoea—Bicalutamide—prostate cancer	0.00298	0.00298	CcSEcCtD
Clavulanate—Thrombocytopenia—Goserelin—prostate cancer	0.00296	0.00296	CcSEcCtD
Clavulanate—Urticaria—Ethinyl Estradiol—prostate cancer	0.00292	0.00292	CcSEcCtD
Clavulanate—Stevens-Johnson syndrome—Etoposide—prostate cancer	0.00289	0.00289	CcSEcCtD
Clavulanate—Toxic epidermal necrolysis—Docetaxel—prostate cancer	0.00283	0.00283	CcSEcCtD
Clavulanate—Hypokalaemia—Capecitabine—prostate cancer	0.00277	0.00277	CcSEcCtD
Clavulanate—Vomiting—Bicalutamide—prostate cancer	0.00277	0.00277	CcSEcCtD
Clavulanate—Rash—Bicalutamide—prostate cancer	0.00274	0.00274	CcSEcCtD
Clavulanate—Toxic epidermal necrolysis—Capecitabine—prostate cancer	0.00274	0.00274	CcSEcCtD
Clavulanate—Dermatitis—Bicalutamide—prostate cancer	0.00274	0.00274	CcSEcCtD
Clavulanate—Hypersensitivity—Ethinyl Estradiol—prostate cancer	0.00271	0.00271	CcSEcCtD
Clavulanate—Pruritus—Ethinyl Estradiol—prostate cancer	0.0026	0.0026	CcSEcCtD
Clavulanate—Pain—Goserelin—prostate cancer	0.00259	0.00259	CcSEcCtD
Clavulanate—Nausea—Bicalutamide—prostate cancer	0.00258	0.00258	CcSEcCtD
Clavulanate—Pain—Conjugated Estrogens—prostate cancer	0.00256	0.00256	CcSEcCtD
Clavulanate—Diarrhoea—Ethinyl Estradiol—prostate cancer	0.00252	0.00252	CcSEcCtD
Clavulanate—Erythema multiforme—Etoposide—prostate cancer	0.00247	0.00247	CcSEcCtD
Clavulanate—Hypokalaemia—Prednisone—prostate cancer	0.00247	0.00247	CcSEcCtD
Clavulanate—Leukopenia—Mitoxantrone—prostate cancer	0.00245	0.00245	CcSEcCtD
Clavulanate—Thrombophlebitis—Epirubicin—prostate cancer	0.00245	0.00245	CcSEcCtD
Clavulanate—Urticaria—Goserelin—prostate cancer	0.0024	0.0024	CcSEcCtD
Clavulanate—Stevens-Johnson syndrome—Docetaxel—prostate cancer	0.0024	0.0024	CcSEcCtD
Clavulanate—Anaphylactic shock—Estradiol—prostate cancer	0.0024	0.0024	CcSEcCtD
Clavulanate—Urticaria—Conjugated Estrogens—prostate cancer	0.00238	0.00238	CcSEcCtD
Clavulanate—Convulsion—Mitoxantrone—prostate cancer	0.00237	0.00237	CcSEcCtD
Clavulanate—Vomiting—Ethinyl Estradiol—prostate cancer	0.00234	0.00234	CcSEcCtD
Clavulanate—Stevens-Johnson syndrome—Capecitabine—prostate cancer	0.00233	0.00233	CcSEcCtD
Clavulanate—Rash—Ethinyl Estradiol—prostate cancer	0.00232	0.00232	CcSEcCtD
Clavulanate—Dermatitis—Ethinyl Estradiol—prostate cancer	0.00232	0.00232	CcSEcCtD
Clavulanate—Thrombophlebitis—Doxorubicin—prostate cancer	0.00227	0.00227	CcSEcCtD
Clavulanate—Anaphylactic shock—Mitoxantrone—prostate cancer	0.00224	0.00224	CcSEcCtD
Clavulanate—Hypersensitivity—Goserelin—prostate cancer	0.00223	0.00223	CcSEcCtD
Clavulanate—Hypersensitivity—Conjugated Estrogens—prostate cancer	0.00221	0.00221	CcSEcCtD
Clavulanate—Thrombocytopenia—Mitoxantrone—prostate cancer	0.00219	0.00219	CcSEcCtD
Clavulanate—Haemoglobin—Docetaxel—prostate cancer	0.00219	0.00219	CcSEcCtD
Clavulanate—Nausea—Ethinyl Estradiol—prostate cancer	0.00218	0.00218	CcSEcCtD
Clavulanate—Hepatitis—Docetaxel—prostate cancer	0.00217	0.00217	CcSEcCtD
Clavulanate—Haemorrhage—Docetaxel—prostate cancer	0.00217	0.00217	CcSEcCtD
Clavulanate—Pruritus—Goserelin—prostate cancer	0.00214	0.00214	CcSEcCtD
Clavulanate—Pruritus—Conjugated Estrogens—prostate cancer	0.00212	0.00212	CcSEcCtD
Clavulanate—Haemoglobin—Capecitabine—prostate cancer	0.00212	0.00212	CcSEcCtD
Clavulanate—Haemorrhage—Capecitabine—prostate cancer	0.00211	0.00211	CcSEcCtD
Clavulanate—Hepatitis—Capecitabine—prostate cancer	0.00211	0.00211	CcSEcCtD
Clavulanate—Diarrhoea—Goserelin—prostate cancer	0.00207	0.00207	CcSEcCtD
Clavulanate—Erythema multiforme—Docetaxel—prostate cancer	0.00206	0.00206	CcSEcCtD
Clavulanate—Pain—Estradiol—prostate cancer	0.00205	0.00205	CcSEcCtD
Clavulanate—Diarrhoea—Conjugated Estrogens—prostate cancer	0.00205	0.00205	CcSEcCtD
Clavulanate—Leukopenia—Etoposide—prostate cancer	0.00204	0.00204	CcSEcCtD
Clavulanate—Erythema multiforme—Capecitabine—prostate cancer	0.00199	0.00199	CcSEcCtD
Clavulanate—Convulsion—Etoposide—prostate cancer	0.00197	0.00197	CcSEcCtD
Clavulanate—Hypokalaemia—Epirubicin—prostate cancer	0.00193	0.00193	CcSEcCtD
Clavulanate—Vomiting—Goserelin—prostate cancer	0.00192	0.00192	CcSEcCtD
Clavulanate—Pain—Mitoxantrone—prostate cancer	0.00191	0.00191	CcSEcCtD
Clavulanate—Toxic epidermal necrolysis—Epirubicin—prostate cancer	0.00191	0.00191	CcSEcCtD
Clavulanate—Rash—Goserelin—prostate cancer	0.00191	0.00191	CcSEcCtD
Clavulanate—Dermatitis—Goserelin—prostate cancer	0.00191	0.00191	CcSEcCtD
Clavulanate—Vomiting—Conjugated Estrogens—prostate cancer	0.00191	0.00191	CcSEcCtD
Clavulanate—Urticaria—Estradiol—prostate cancer	0.00191	0.00191	CcSEcCtD
Clavulanate—Rash—Conjugated Estrogens—prostate cancer	0.00189	0.00189	CcSEcCtD
Clavulanate—Dermatitis—Conjugated Estrogens—prostate cancer	0.00189	0.00189	CcSEcCtD
Clavulanate—Haemoglobin—Prednisone—prostate cancer	0.00189	0.00189	CcSEcCtD
Clavulanate—Haemorrhage—Prednisone—prostate cancer	0.00188	0.00188	CcSEcCtD
Clavulanate—Anaphylactic shock—Etoposide—prostate cancer	0.00186	0.00186	CcSEcCtD
Clavulanate—Thrombocytopenia—Etoposide—prostate cancer	0.00182	0.00182	CcSEcCtD
Clavulanate—Eosinophilia—Epirubicin—prostate cancer	0.00181	0.00181	CcSEcCtD
Clavulanate—Nausea—Goserelin—prostate cancer	0.0018	0.0018	CcSEcCtD
Clavulanate—Hypokalaemia—Doxorubicin—prostate cancer	0.00179	0.00179	CcSEcCtD
Clavulanate—Nausea—Conjugated Estrogens—prostate cancer	0.00178	0.00178	CcSEcCtD
Clavulanate—Urticaria—Mitoxantrone—prostate cancer	0.00178	0.00178	CcSEcCtD
Clavulanate—Hypersensitivity—Estradiol—prostate cancer	0.00177	0.00177	CcSEcCtD
Clavulanate—Toxic epidermal necrolysis—Doxorubicin—prostate cancer	0.00177	0.00177	CcSEcCtD
Clavulanate—Pruritus—Estradiol—prostate cancer	0.0017	0.0017	CcSEcCtD
Clavulanate—Leukopenia—Docetaxel—prostate cancer	0.00169	0.00169	CcSEcCtD
Clavulanate—Eosinophilia—Doxorubicin—prostate cancer	0.00168	0.00168	CcSEcCtD
Clavulanate—Hypersensitivity—Mitoxantrone—prostate cancer	0.00165	0.00165	CcSEcCtD
Clavulanate—Diarrhoea—Estradiol—prostate cancer	0.00164	0.00164	CcSEcCtD
Clavulanate—Leukopenia—Capecitabine—prostate cancer	0.00164	0.00164	CcSEcCtD
Clavulanate—Convulsion—Docetaxel—prostate cancer	0.00164	0.00164	CcSEcCtD
Clavulanate—Stevens-Johnson syndrome—Epirubicin—prostate cancer	0.00162	0.00162	CcSEcCtD
Clavulanate—Pain—Etoposide—prostate cancer	0.00159	0.00159	CcSEcCtD
Clavulanate—Anaphylactic shock—Docetaxel—prostate cancer	0.00155	0.00155	CcSEcCtD
Clavulanate—Diarrhoea—Mitoxantrone—prostate cancer	0.00153	0.00153	CcSEcCtD
Clavulanate—Vomiting—Estradiol—prostate cancer	0.00153	0.00153	CcSEcCtD
Clavulanate—Thrombocytopenia—Docetaxel—prostate cancer	0.00151	0.00151	CcSEcCtD
Clavulanate—Rash—Estradiol—prostate cancer	0.00151	0.00151	CcSEcCtD
Clavulanate—Dermatitis—Estradiol—prostate cancer	0.00151	0.00151	CcSEcCtD
Clavulanate—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	0.0015	0.0015	CcSEcCtD
Clavulanate—Urticaria—Etoposide—prostate cancer	0.00148	0.00148	CcSEcCtD
Clavulanate—Haemoglobin—Epirubicin—prostate cancer	0.00147	0.00147	CcSEcCtD
Clavulanate—Haemorrhage—Epirubicin—prostate cancer	0.00147	0.00147	CcSEcCtD
Clavulanate—Hepatitis—Epirubicin—prostate cancer	0.00147	0.00147	CcSEcCtD
Clavulanate—Thrombocytopenia—Capecitabine—prostate cancer	0.00146	0.00146	CcSEcCtD
Clavulanate—Nausea—Estradiol—prostate cancer	0.00142	0.00142	CcSEcCtD
Clavulanate—Vomiting—Mitoxantrone—prostate cancer	0.00142	0.00142	CcSEcCtD
Clavulanate—Convulsion—Prednisone—prostate cancer	0.00141	0.00141	CcSEcCtD
Clavulanate—Rash—Mitoxantrone—prostate cancer	0.00141	0.00141	CcSEcCtD
Clavulanate—Dermatitis—Mitoxantrone—prostate cancer	0.00141	0.00141	CcSEcCtD
Clavulanate—Erythema multiforme—Epirubicin—prostate cancer	0.00139	0.00139	CcSEcCtD
Clavulanate—Hypersensitivity—Etoposide—prostate cancer	0.00137	0.00137	CcSEcCtD
Clavulanate—Haemoglobin—Doxorubicin—prostate cancer	0.00136	0.00136	CcSEcCtD
Clavulanate—Haemorrhage—Doxorubicin—prostate cancer	0.00136	0.00136	CcSEcCtD
Clavulanate—Hepatitis—Doxorubicin—prostate cancer	0.00136	0.00136	CcSEcCtD
Clavulanate—Anaphylactic shock—Prednisone—prostate cancer	0.00133	0.00133	CcSEcCtD
Clavulanate—Nausea—Mitoxantrone—prostate cancer	0.00133	0.00133	CcSEcCtD
Clavulanate—Pain—Docetaxel—prostate cancer	0.00132	0.00132	CcSEcCtD
Clavulanate—Pruritus—Etoposide—prostate cancer	0.00132	0.00132	CcSEcCtD
Clavulanate—Erythema multiforme—Doxorubicin—prostate cancer	0.00128	0.00128	CcSEcCtD
Clavulanate—Pain—Capecitabine—prostate cancer	0.00128	0.00128	CcSEcCtD
Clavulanate—Diarrhoea—Etoposide—prostate cancer	0.00127	0.00127	CcSEcCtD
Clavulanate—Urticaria—Capecitabine—prostate cancer	0.00119	0.00119	CcSEcCtD
Clavulanate—Vomiting—Etoposide—prostate cancer	0.00118	0.00118	CcSEcCtD
Clavulanate—Rash—Etoposide—prostate cancer	0.00117	0.00117	CcSEcCtD
Clavulanate—Dermatitis—Etoposide—prostate cancer	0.00117	0.00117	CcSEcCtD
Clavulanate—Leukopenia—Epirubicin—prostate cancer	0.00114	0.00114	CcSEcCtD
Clavulanate—Hypersensitivity—Docetaxel—prostate cancer	0.00114	0.00114	CcSEcCtD
Clavulanate—Convulsion—Epirubicin—prostate cancer	0.00111	0.00111	CcSEcCtD
Clavulanate—Nausea—Etoposide—prostate cancer	0.0011	0.0011	CcSEcCtD
Clavulanate—Hypersensitivity—Capecitabine—prostate cancer	0.0011	0.0011	CcSEcCtD
Clavulanate—Pruritus—Docetaxel—prostate cancer	0.00109	0.00109	CcSEcCtD
Clavulanate—Urticaria—Prednisone—prostate cancer	0.00106	0.00106	CcSEcCtD
Clavulanate—Pruritus—Capecitabine—prostate cancer	0.00106	0.00106	CcSEcCtD
Clavulanate—Leukopenia—Doxorubicin—prostate cancer	0.00106	0.00106	CcSEcCtD
Clavulanate—Diarrhoea—Docetaxel—prostate cancer	0.00106	0.00106	CcSEcCtD
Clavulanate—Anaphylactic shock—Epirubicin—prostate cancer	0.00104	0.00104	CcSEcCtD
Clavulanate—Convulsion—Doxorubicin—prostate cancer	0.00102	0.00102	CcSEcCtD
Clavulanate—Diarrhoea—Capecitabine—prostate cancer	0.00102	0.00102	CcSEcCtD
Clavulanate—Thrombocytopenia—Epirubicin—prostate cancer	0.00102	0.00102	CcSEcCtD
Clavulanate—Vomiting—Docetaxel—prostate cancer	0.000982	0.000982	CcSEcCtD
Clavulanate—Hypersensitivity—Prednisone—prostate cancer	0.000982	0.000982	CcSEcCtD
Clavulanate—Rash—Docetaxel—prostate cancer	0.000974	0.000974	CcSEcCtD
Clavulanate—Dermatitis—Docetaxel—prostate cancer	0.000973	0.000973	CcSEcCtD
Clavulanate—Anaphylactic shock—Doxorubicin—prostate cancer	0.000964	0.000964	CcSEcCtD
Clavulanate—Vomiting—Capecitabine—prostate cancer	0.000951	0.000951	CcSEcCtD
Clavulanate—Thrombocytopenia—Doxorubicin—prostate cancer	0.000944	0.000944	CcSEcCtD
Clavulanate—Rash—Capecitabine—prostate cancer	0.000943	0.000943	CcSEcCtD
Clavulanate—Pruritus—Prednisone—prostate cancer	0.000943	0.000943	CcSEcCtD
Clavulanate—Dermatitis—Capecitabine—prostate cancer	0.000942	0.000942	CcSEcCtD
Clavulanate—Nausea—Docetaxel—prostate cancer	0.000918	0.000918	CcSEcCtD
Clavulanate—Diarrhoea—Prednisone—prostate cancer	0.000912	0.000912	CcSEcCtD
Clavulanate—Pain—Epirubicin—prostate cancer	0.000891	0.000891	CcSEcCtD
Clavulanate—Nausea—Capecitabine—prostate cancer	0.000889	0.000889	CcSEcCtD
Clavulanate—Vomiting—Prednisone—prostate cancer	0.000847	0.000847	CcSEcCtD
Clavulanate—Rash—Prednisone—prostate cancer	0.00084	0.00084	CcSEcCtD
Clavulanate—Dermatitis—Prednisone—prostate cancer	0.000839	0.000839	CcSEcCtD
Clavulanate—Urticaria—Epirubicin—prostate cancer	0.000828	0.000828	CcSEcCtD
Clavulanate—Pain—Doxorubicin—prostate cancer	0.000825	0.000825	CcSEcCtD
Clavulanate—Nausea—Prednisone—prostate cancer	0.000792	0.000792	CcSEcCtD
Clavulanate—Hypersensitivity—Epirubicin—prostate cancer	0.000768	0.000768	CcSEcCtD
Clavulanate—Urticaria—Doxorubicin—prostate cancer	0.000766	0.000766	CcSEcCtD
Clavulanate—Pruritus—Epirubicin—prostate cancer	0.000737	0.000737	CcSEcCtD
Clavulanate—Diarrhoea—Epirubicin—prostate cancer	0.000713	0.000713	CcSEcCtD
Clavulanate—Hypersensitivity—Doxorubicin—prostate cancer	0.00071	0.00071	CcSEcCtD
Clavulanate—Pruritus—Doxorubicin—prostate cancer	0.000682	0.000682	CcSEcCtD
Clavulanate—Vomiting—Epirubicin—prostate cancer	0.000663	0.000663	CcSEcCtD
Clavulanate—Diarrhoea—Doxorubicin—prostate cancer	0.00066	0.00066	CcSEcCtD
Clavulanate—Rash—Epirubicin—prostate cancer	0.000657	0.000657	CcSEcCtD
Clavulanate—Dermatitis—Epirubicin—prostate cancer	0.000657	0.000657	CcSEcCtD
Clavulanate—Nausea—Epirubicin—prostate cancer	0.000619	0.000619	CcSEcCtD
Clavulanate—Vomiting—Doxorubicin—prostate cancer	0.000613	0.000613	CcSEcCtD
Clavulanate—Rash—Doxorubicin—prostate cancer	0.000608	0.000608	CcSEcCtD
Clavulanate—Dermatitis—Doxorubicin—prostate cancer	0.000607	0.000607	CcSEcCtD
Clavulanate—Nausea—Doxorubicin—prostate cancer	0.000573	0.000573	CcSEcCtD
